Learn More
recognizes a distinct category of myelodysplastic/myeloproliferative neoplasms (MDS/ MPN), for those patients at diagnosis with clinical, morphologic and laboratory features which overlap both those of MDS and MPN.(1) Four hematopathologic diagnoses exist within this category; chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia(More)
This study of vosaroxin evaluated dose-limiting toxicity (DLT), maximum-tolerated dose (MTD), pharmacokinetics (PK), clinical activity and pharmacodynamics in relapsed/refractory leukemia. Dosing was weekly (days 1, 8 and 15) or twice weekly (days 1, 4, 8 and 11). Seventy-three treated patients had a median age of 65 years, 85% had acute myeloid leukemia(More)
  • 1